Deadly Proteins Behind Mad Cow Disease Might Help Us Fight Superbugs
The next frontier of antibiotics might come from an unexpected place. Recent research identifies potential antibiotic candidates from inside prions—proteins capable of causing some of the deadliest brain infections ever known, such as mad cow disease.
Scientists at the University of Pennsylvania used artificial intelligence to rapidly search hundreds of prions and prion-like proteins for peptides with antibacterial activity. They found several dozen promising candidates, two of which have already shown results treating bacterial infections in mice.
The team’s findings establish “prion-related proteins as a productive source space for antibiotic discovery,” the scientists wrote in their paper, published late last week in the journal Nature Microbiology.
Good guy prions?
Prions are some of the strangest things around. They’re the misfolded form of a protein naturally found in the body. When a prion comes across its “normal” counterpart, it can somehow induce the latter to turn into a prion itself, almost like a zombie infection.
Classic prion disorders like mad cow disease and Creutzfeldt-Jakob disease are caused by the steady accumulation of one particular type of protein, aptly named the prion protein; these disorders are universally fatal. Some scientists have also argued that other neurodegenerative conditions, such as Alzheimer’s disease, are caused by other kinds of misfolded proteins that act in a similar way to prions.
According to the study researchers, there’s growing evidence that prions and prion-like proteins are more than just harbingers of death. Studies have found that the normal prion protein and the prion-like amyloid beta (one of the drivers of Alzheimer’s) can have antimicrobial activity, for instance. So the team decided to conduct a sweeping analysis looking for antimicrobial peptide fragments within these proteins.
The researchers had previously built an AI model intended to predict the antimicrobial activity of any given peptide fragment, named APEX 1.1. Then they let APEX scan through 19.3 million short peptide fragments found in 2,897 prion and prion-like proteins. They initially uncovered 1,179 candidates, which the team narrowed down to 75 that showed the most potential. Of these, 59 were able to inhibit the growth of at least one bacterial germ in the lab, including 42 that did so at low levels (important for dosing considerations).
Finally, the researchers tested two of the strongest candidates on the skin of mice infected with Acinetobacter baumannii, a common source of drug-resistant infections in people. The candidates appeared to be roughly as effective as polymyxin B, an existing antibiotic often used as a last resort drug for certain drug-resistant infections.
The researchers have coined these antibacterial fragments collected from prions as “prionins.”
The future of prionins
More research is obviously needed to verify whether the team’s prionins can actually work as hoped—and safely—in people. The researchers also note their findings don’t settle the open question as to whether prions or prion-like proteins naturally tackle bacterial infections in our body.
At the same time, they do argue their work provides a strong proof of concept that prionins identified through AI can be viable antibiotic candidates for further testing.
“For a long time, drug discovery has been limited not only by what we can test, but by where we choose to look,” said senior study author César de la Fuente, director of the Machine Biology Group at the University of Pennsylvania Perelman School of Medicine, in a statement from the university. “AI is changing that. It gives us a way to search the hidden layers of biology and ask whether molecules associated with one story—in this case, disease—may also carry another story with therapeutic potential.”
With any luck, the proteins known for causing the scariest diseases around could someday turn into our antibacterial allies.
#Deadly #Proteins #Mad #Cow #Disease #Fight #Superbugsantibiotic resistance,experimental drugs,prions
The next frontier of antibiotics might come from an unexpected place. Recent research identifies potential antibiotic candidates from inside prions—proteins capable of causing some of the deadliest brain infections ever known, such as mad cow disease.
Scientists at the University of Pennsylvania used artificial intelligence to rapidly search hundreds of prions and prion-like proteins for peptides with antibacterial activity. They found several dozen promising candidates, two of which have already shown results treating bacterial infections in mice.
The team’s findings establish “prion-related proteins as a productive source space for antibiotic discovery,” the scientists wrote in their paper, published late last week in the journal Nature Microbiology.
Good guy prions?
Prions are some of the strangest things around. They’re the misfolded form of a protein naturally found in the body. When a prion comes across its “normal” counterpart, it can somehow induce the latter to turn into a prion itself, almost like a zombie infection.
Classic prion disorders like mad cow disease and Creutzfeldt-Jakob disease are caused by the steady accumulation of one particular type of protein, aptly named the prion protein; these disorders are universally fatal. Some scientists have also argued that other neurodegenerative conditions, such as Alzheimer’s disease, are caused by other kinds of misfolded proteins that act in a similar way to prions.
According to the study researchers, there’s growing evidence that prions and prion-like proteins are more than just harbingers of death. Studies have found that the normal prion protein and the prion-like amyloid beta (one of the drivers of Alzheimer’s) can have antimicrobial activity, for instance. So the team decided to conduct a sweeping analysis looking for antimicrobial peptide fragments within these proteins.
The researchers had previously built an AI model intended to predict the antimicrobial activity of any given peptide fragment, named APEX 1.1. Then they let APEX scan through 19.3 million short peptide fragments found in 2,897 prion and prion-like proteins. They initially uncovered 1,179 candidates, which the team narrowed down to 75 that showed the most potential. Of these, 59 were able to inhibit the growth of at least one bacterial germ in the lab, including 42 that did so at low levels (important for dosing considerations).
Finally, the researchers tested two of the strongest candidates on the skin of mice infected with Acinetobacter baumannii, a common source of drug-resistant infections in people. The candidates appeared to be roughly as effective as polymyxin B, an existing antibiotic often used as a last resort drug for certain drug-resistant infections.
The researchers have coined these antibacterial fragments collected from prions as “prionins.”
The future of prionins
More research is obviously needed to verify whether the team’s prionins can actually work as hoped—and safely—in people. The researchers also note their findings don’t settle the open question as to whether prions or prion-like proteins naturally tackle bacterial infections in our body.
At the same time, they do argue their work provides a strong proof of concept that prionins identified through AI can be viable antibiotic candidates for further testing.
“For a long time, drug discovery has been limited not only by what we can test, but by where we choose to look,” said senior study author César de la Fuente, director of the Machine Biology Group at the University of Pennsylvania Perelman School of Medicine, in a statement from the university. “AI is changing that. It gives us a way to search the hidden layers of biology and ask whether molecules associated with one story—in this case, disease—may also carry another story with therapeutic potential.”
With any luck, the proteins known for causing the scariest diseases around could someday turn into our antibacterial allies.
![This former notorious red-light district is now one of the world’s top AI hubs | TechCrunch
What every U.K. AI startup wants to know these days is, how can I get office space in King’s Cross?
The area is so hot that a VC firm allegedly recently won a deal by promising a founder office space in the neighborhood. “We stop at nothing to win deals [for] and to support” founders, “including helping them source office space when needed,” the firm told me when asked about the rumor, declining to confirm or deny any details.
The neighborhood’s popularity began back in 2016 when DeepMind — then newly acquired by Google — moved in. Soon after, a flood of AI startups followed, wanting to be around the Google DeepMind magic. Today, they hope to take advantage of the cluster of AI talent there.
This has transformed King’s Cross into one of the world’s top AI hubs, rivaled only by San Francisco and Beijing. Around London, it’s known by the sobriquet “Knowledge Quarter,” as it’s home to names like OpenAI, Meta, Isomorphic Labs, Cusp AI, Wayne, Recursive, and, a little farther down the road, Synthesia and Anthropic. The European Technology Network (ETN) just moved into a glossy new office nearby, while University College London sits around the corner.
Mixed in with the new developments are trendy food spots like Hoppers and BAO. Hop a train from King’s Cross, and founders can be in Cambridge in 45 minutes to source talent or can be in Paris in two hours to strike a deal.
Who would have guessed that a little more than 20 years ago, this was one of the seediest areas in London?
“In the ’80s, crack and heroin made the area a major narcotics market,” Hussein Kanji, an investor at Hoxton Ventures, said, recalling syringes in tree trunks and gangs patrolling the streets. “In 1982, the local church was occupied by the English Collective of Prostitutes for 12 straight days.” Then, in the early 2000s, a real estate developer had a dream and, well, “now it is the AI hotbed of the United Kingdom,” Kanji said. “What a change.” Around 18 months ago, his portfolio company BioCorteX moved from the neighborhood Holborn to the Jellicoe building in King’s Cross, hoping to be near the action. “Lots going on in London right now,” Nik Sharma, co-founder of BioCorteX, told me. “Lots of hyperscalers moving in.” That includes, reportedly, Jeff Bezos’ AI company Prometheus, which is also said to be in talks to move into the Jellicoe.
There are around 3,600 AI startups in London, which, together, have raised around .1 billion out of the .8 billion raised in the city since late July, according to Dealroom. Since the start of June, AI-related startups have leased more than 1 million square feet of office space in London, according to the real estate firm Knight Frank. With that, prime rents in King’s Cross have risen 18% over the past three years, Chris Dunn, a commercial insight associate at the firm, told me. That percentage represents only the largest leases encompassing at least 10,000 square feet, like the ones OpenAI and Prometheus are signing. The shorter deals go for even more, he said, and now the vacancy rate for conventional office space is just 0.9%. “Demand has outstripped supply,” he continued.
Today, one of the big topics of the area is sovereignty. It was a wake-up call for many when Anthropic shut off access to Mythos and Fable this summer, leaving some in the ecosystem to conclude: “We’d better look after ourselves,” Saul Klein, co-founder of the VC firm Phoenix Court, told me.
Phoenix Court is located in the King’s Cross area and has three portfolio companies in the vicinity, including Olix (which just announced a .3 billion valuation), Early Health and CoMind. Robin Klein, co-founder of the firm, said the shutdown of Fable and Mythos access was a “small but sharp reminder that Europe can’t simply rent its AI capabilities and capacity; it needs to build and hold some of its own.” King’s Cross, he said, is where much of this building is actually happening.
“The bigger question,” he continued, “is whether the U.K. builds the infrastructure, compute, energy, capital, to make this self-reliance durable, rather than just hosting outposts of U.S. labs.”
Image Credits:Phoenix Court
Top founders want to stay
Simon Kohl, founder of Latent Labs, has offices in King’s Cross and San Francisco. The London office, at the moment, is growing faster, and he’s more bullish than ever on the ecosystem, he said. “The mood right now feels less like London trying to catch up and more like London becoming one of the default places to start a serious AI company,” he said. Look around and you are likely to see Wayve testing its autonomous cars. Founded in 2017 by co-founder Alex Kendall, the unicorn is one of London’s biggest success stories.
“Ten years ago, building a frontier AI company from London felt like an unusual choice,” Kendall told me. “Now it feels like an obvious one.” Wayve moved into King’s Cross in 2018 looking for a space that could double as a garage — “a rare combination in Central London,” Kendall said. He has watched the ecosystem mature around him — and it’s now evident that a startup can stay in London, raise serious capital, hire world-class AI talent, and remain globally competitive, he said. Down the street from Anthropic’s new 158,000-square-foot office is the AI agent builder Sierra and the AI video platform Synthesia.
Laura Gonzalez Florez, Synthesia’s chief of staff and head of people, says the company moved into its glossy new office building a year ago to accommodate its growing team. They were drawn to the area for the same reason as everyone else: “It’s very close to the airport … very close to where a lot of investors are,” she said.
Image Credits:Synthesia
Around two-thirds of Synthesia’s engineers are remote, Gonzalez Florez said, letting the company tap into an affordable, international, and diverse talent pool and helping it scale faster. “From London, we can hire and work, without any problem, people from anywhere, from Slovenia to Portugal,” she said.
Unsurprisingly, London’s AI boom is also causing a talent war.U.K. AI job postings have skyrocketed in the past few years, per data from PwC. When Anthropic announced it moved into town earlier this year, it listed, for example, a salary range of £260,000 to £630,000 for a machine learning research engineer when the average salary in London for the same role is around £102,000. Some founders in the U.K., like those in Silicon Valley, are being forced to raise more and bigger rounds to keep up.
“The real test is whether more globally significant AI companies are founded, funded, and scaled from the U.K., while continuing to attract the world’s best talent to build them here,” Zain Ali, founder of the King’s Cross-based AI legal firm Centuro, told me. “If that continues to happen, King’s Cross won’t just be an AI hub. It’ll become one of the U.K.’s most important strategic assets.”
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.#Thisformernotorious #redlight #districtis #nowone #worlds #top #hubs #TechCrunchUK This former notorious red-light district is now one of the world’s top AI hubs | TechCrunch
What every U.K. AI startup wants to know these days is, how can I get office space in King’s Cross?
The area is so hot that a VC firm allegedly recently won a deal by promising a founder office space in the neighborhood. “We stop at nothing to win deals [for] and to support” founders, “including helping them source office space when needed,” the firm told me when asked about the rumor, declining to confirm or deny any details.
The neighborhood’s popularity began back in 2016 when DeepMind — then newly acquired by Google — moved in. Soon after, a flood of AI startups followed, wanting to be around the Google DeepMind magic. Today, they hope to take advantage of the cluster of AI talent there.
This has transformed King’s Cross into one of the world’s top AI hubs, rivaled only by San Francisco and Beijing. Around London, it’s known by the sobriquet “Knowledge Quarter,” as it’s home to names like OpenAI, Meta, Isomorphic Labs, Cusp AI, Wayne, Recursive, and, a little farther down the road, Synthesia and Anthropic. The European Technology Network (ETN) just moved into a glossy new office nearby, while University College London sits around the corner.
Mixed in with the new developments are trendy food spots like Hoppers and BAO. Hop a train from King’s Cross, and founders can be in Cambridge in 45 minutes to source talent or can be in Paris in two hours to strike a deal.
Who would have guessed that a little more than 20 years ago, this was one of the seediest areas in London?
“In the ’80s, crack and heroin made the area a major narcotics market,” Hussein Kanji, an investor at Hoxton Ventures, said, recalling syringes in tree trunks and gangs patrolling the streets. “In 1982, the local church was occupied by the English Collective of Prostitutes for 12 straight days.” Then, in the early 2000s, a real estate developer had a dream and, well, “now it is the AI hotbed of the United Kingdom,” Kanji said. “What a change.” Around 18 months ago, his portfolio company BioCorteX moved from the neighborhood Holborn to the Jellicoe building in King’s Cross, hoping to be near the action. “Lots going on in London right now,” Nik Sharma, co-founder of BioCorteX, told me. “Lots of hyperscalers moving in.” That includes, reportedly, Jeff Bezos’ AI company Prometheus, which is also said to be in talks to move into the Jellicoe.
There are around 3,600 AI startups in London, which, together, have raised around .1 billion out of the .8 billion raised in the city since late July, according to Dealroom. Since the start of June, AI-related startups have leased more than 1 million square feet of office space in London, according to the real estate firm Knight Frank. With that, prime rents in King’s Cross have risen 18% over the past three years, Chris Dunn, a commercial insight associate at the firm, told me. That percentage represents only the largest leases encompassing at least 10,000 square feet, like the ones OpenAI and Prometheus are signing. The shorter deals go for even more, he said, and now the vacancy rate for conventional office space is just 0.9%. “Demand has outstripped supply,” he continued.
Today, one of the big topics of the area is sovereignty. It was a wake-up call for many when Anthropic shut off access to Mythos and Fable this summer, leaving some in the ecosystem to conclude: “We’d better look after ourselves,” Saul Klein, co-founder of the VC firm Phoenix Court, told me.
Phoenix Court is located in the King’s Cross area and has three portfolio companies in the vicinity, including Olix (which just announced a .3 billion valuation), Early Health and CoMind. Robin Klein, co-founder of the firm, said the shutdown of Fable and Mythos access was a “small but sharp reminder that Europe can’t simply rent its AI capabilities and capacity; it needs to build and hold some of its own.” King’s Cross, he said, is where much of this building is actually happening.
“The bigger question,” he continued, “is whether the U.K. builds the infrastructure, compute, energy, capital, to make this self-reliance durable, rather than just hosting outposts of U.S. labs.”
Image Credits:Phoenix Court
Top founders want to stay
Simon Kohl, founder of Latent Labs, has offices in King’s Cross and San Francisco. The London office, at the moment, is growing faster, and he’s more bullish than ever on the ecosystem, he said. “The mood right now feels less like London trying to catch up and more like London becoming one of the default places to start a serious AI company,” he said. Look around and you are likely to see Wayve testing its autonomous cars. Founded in 2017 by co-founder Alex Kendall, the unicorn is one of London’s biggest success stories.
“Ten years ago, building a frontier AI company from London felt like an unusual choice,” Kendall told me. “Now it feels like an obvious one.” Wayve moved into King’s Cross in 2018 looking for a space that could double as a garage — “a rare combination in Central London,” Kendall said. He has watched the ecosystem mature around him — and it’s now evident that a startup can stay in London, raise serious capital, hire world-class AI talent, and remain globally competitive, he said. Down the street from Anthropic’s new 158,000-square-foot office is the AI agent builder Sierra and the AI video platform Synthesia.
Laura Gonzalez Florez, Synthesia’s chief of staff and head of people, says the company moved into its glossy new office building a year ago to accommodate its growing team. They were drawn to the area for the same reason as everyone else: “It’s very close to the airport … very close to where a lot of investors are,” she said.
Image Credits:Synthesia
Around two-thirds of Synthesia’s engineers are remote, Gonzalez Florez said, letting the company tap into an affordable, international, and diverse talent pool and helping it scale faster. “From London, we can hire and work, without any problem, people from anywhere, from Slovenia to Portugal,” she said.
Unsurprisingly, London’s AI boom is also causing a talent war.U.K. AI job postings have skyrocketed in the past few years, per data from PwC. When Anthropic announced it moved into town earlier this year, it listed, for example, a salary range of £260,000 to £630,000 for a machine learning research engineer when the average salary in London for the same role is around £102,000. Some founders in the U.K., like those in Silicon Valley, are being forced to raise more and bigger rounds to keep up.
“The real test is whether more globally significant AI companies are founded, funded, and scaled from the U.K., while continuing to attract the world’s best talent to build them here,” Zain Ali, founder of the King’s Cross-based AI legal firm Centuro, told me. “If that continues to happen, King’s Cross won’t just be an AI hub. It’ll become one of the U.K.’s most important strategic assets.”
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.#Thisformernotorious #redlight #districtis #nowone #worlds #top #hubs #TechCrunchUK](https://techcrunch.com/wp-content/uploads/2026/08/DM9A2852.jpg?w=680)

Post Comment